Tumor-Targeted Salmonella

Genetically engineered Salmonella offer an intriguing new approach to selectively target solid tumors, including melanoma, lung, colon, breast, kidney and liver. These bacteria target tumors after systemic administration and selectively replicate within them. Specificity for tumors is often more than 1,000 times greater than for any other tissue. Auxotrophic mutations make these bacteria highly safe and form the basis for maintaining tumor specificity. An altered lipid greatly reduces the potential for septic shock yet also retains the antitumor properties of these bacteria. These bacteria have innate antitumor activity towards both primary and metastatic tumors and the ability to deliver proteins capable of activating chemotherapeutic agents directly within tumors. The delay in tumor growth results in mice that survive up to twice as long. These bacteria are susceptible to a wide range of antibiotics, allowing external control of the vector after administration. The combination of these features within a single vector seems especially surprising considering their unlikely source.

[1]  P. Trail,et al.  Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. , 1993, Science.

[2]  P. Friedman,et al.  BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells. , 1993, Cancer research.

[3]  K. Joiner Complement evasion by bacteria and parasites. , 1988, Annual review of microbiology.

[4]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[5]  A. Giaccia,et al.  Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. , 1996, Gene therapy.

[6]  R. C. Parker,et al.  Effect of Histolyticus Infection and Toxin on Transplantable Mouse Tumors.∗ , 1947, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[7]  F. Collins,et al.  THE ROUTE OF ENTERIC INFECTION IN NORMAL MICE , 1974, The Journal of experimental medicine.

[8]  C. Siegall Targeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the Le(y) antigen. , 1995, Seminars in cancer biology.

[9]  P. Kourilsky,et al.  Expression of herpes simplex virus type I thymidine kinase gene in Escherichia coli. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. V. Zijl,et al.  Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment , 1997, Gene Therapy.

[11]  R K Jain,et al.  Barriers to drug delivery in solid tumors. , 1994, Scientific American.

[12]  A. Fattaey,et al.  An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells , 1996, Science.

[13]  J. Moese,et al.  ONCOLYSIS BY CLOSTRIDIA. I. ACTIVITY OF CLOSTRIDIUM BUTYRICUM (M-55) AND OTHER NONPATHOGENIC CLOSTRIDIA AGAINST THE EHRLICH CARCINOMA. , 1964, Cancer research.

[14]  R K Jain,et al.  Tumor angiogenesis and interstitial hypertension. , 1996, Cancer research.

[15]  T. Burrows,et al.  The effects of biochemical mutation on the virulence of Bacterium typhosum: the virulence of mutants. , 1950, British journal of experimental pathology.

[16]  T. Miyamoto,et al.  Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. , 1998, The Journal of urology.

[17]  M. Saier,et al.  Salmonella virulence: new clues to intramacrophage survival. , 1990, Trends in biochemical sciences.

[18]  T. Burrows,et al.  The effects of biochemical mutation on the virulence of Bacterium typhosum; the loss of virulence of certain mutants. , 1951, British journal of experimental pathology.

[19]  D. Gericke,et al.  ONCOLYSIS BY CLOSTRIDIA. V. TRANSPLANTED TUMORS OF THE HAMSTER. , 1964, Cancer research.

[20]  B. Stocker,et al.  Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines , 1981, Nature.

[21]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[22]  I. Charles,et al.  A lethal role for lipid A in Salmonella infections , 1998, Molecular microbiology.

[23]  E. Neter,et al.  Clostridial oncolysis in man , 1967 .